DelveInsight’s ‘Endometriosis - Epidemiology Forecast to 2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Endometriosis in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
Geography Covered • The United States • EU5 (Germany, France, Italy, Spain and the United Kingdom) • Japan
Study Period: 2016-2027
Endometriosis Epidemiology The Endometriosis epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. The epidemiology data for Endometriosis are studied through all possible division to give a better understanding about the Disease scenario in 7MM. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.
Endometriosis Epidemiology Segmentation The disease epidemiology covered in the report is segmented by total prevalence, diagnosed population and treatable cases of Endometriosis in 7MM. The DelveInsight report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight. According to DelveInsight, the prevalent cases of Endometriosis in 7 major markets was 13.8 Million in 2016 and, is expected to increase at a significant growth rate during the study period i.e., 2016-2027. Among 7MM United States account for highest incident population of Endometriosis i.e., 7.4 Million followed by United Kingdom.
Report Scope • The report covers detailed overview of Endometriosis explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns • The report provides the insight about the historical and forecasted patient pool for 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan • The Report assesses the disease risk and burden and highlights the unmet needs of Endometriosis • The Report helps to recognize the growth opportunities in the 7MM with respect to the patient population • The report provides the segmentation of the disease epidemiology by total prevalence of Endometriosis, Diagnosed cases as well as treatable population of Endometriosis in 7MM
Key strengths • 10 Year Forecast of Endometriosis epidemiology • 7MM Coverage • Total Prevalent Cases of Endometriosis • Diagnosed and Treatable population of Endometriosis in 7MM
Key assessments • Patient Segmentation • Disease Risk & Burden • Risk of disease by the segmentation • Factors driving growth in a specific patient population
Our reports have been used by over 10K customers, including:
Introduction “Uterine Leiomyoma (Uterine Fibroids) - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2019" report provides comprehensive insights about marketed and Phase III products for Uterine Leiomyoma (Uterine Fibroids) . The report includes information of marketed products including their product...
Renal Diseases Drug Development Pipeline Review, 2018 Summary Chronic kidney disease is the slow loss of kidney function over time. Signs and symptoms of kidney disease include nausea, vomiting, loss of appetite, fatigue and weakness, sleep problems, hiccups and swelling of the feet and ankles. The...
158 pages •
By Roots Analysis Private Ltd.
• Nov 2018
INTRODUCTION Chronic kidney disease (CKD) is characterized by progressive loss of kidney function over a period of time. In most patients suffering from CKD, symptoms (such as swollen ankles, blood in urine and foamy urine) are rarely observed until kidney function has declined by 75%. It is worth highlighting that over...
Amenorrhea Global Clinical Trials Review, H2, 2018 Summary GlobalData’s clinical trial report, “Amenorrhea Global Clinical Trials Review, H2, 2018" provides an overview of Amenorrhea clinical trials scenario.This report provides top line data relating to the clinical trials on Amenorrhea. Report...
Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 188.8.131.52) - Pipeline Review, H2 2018 Summary Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 184.108.40.206)...
145 pages •
By Global Industry Analysts
• Jan 2019
This report analyzes the worldwide markets for Kidney Stone Management Devices in US$ Thousand. The Global market is further analyzed by the following Treatment Modalities: Extracorporeal Shock Wave Lithotripsy, Percutaneous Nephrolithotomy, and Intracorporeal Lithotripsy. The report provides separate comprehensive...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.